These CD19-Cbs–engineered CAR-T cells (Cbstd CAR-T cells) also exhibited better tumor control as compared to the CD19 CAR-engineered T cells (Fig. 3D) with increased persistence (right panel). Here, CD19 is linked to neoplasm.